C Day
C Day
Verified email at ncl.ac.uk
Title
Cited by
Cited by
Year
Steatohepatitis: a tale of two “hits”?
CP Day, OFW James
Gastroenterology 114 (4), 842-845, 1998
50321998
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
P Angulo, JM Hui, G Marchesini, E Bugianesi, J George, GC Farrell, ...
Hepatology 45 (4), 846-854, 2007
21242007
QT dispersion: an indication of arrhythmia risk in patients with long QT intervals.
CP Day, JM McComb, RW Campbell
Heart 63 (6), 342-344, 1990
19521990
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease
G Targher, CP Day, E Bonora
New England Journal of Medicine 363 (14), 1341-1350, 2010
17562010
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
GP Aithal, CP Day, PJL Kesteven, AK Daly
The Lancet 353 (9154), 717-719, 1999
15741999
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients
G Targher, L Bertolini, R Padovani, S Rodella, R Tessari, L Zenari, C Day, ...
Diabetes care 30 (5), 1212-1218, 2007
11812007
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
QM Anstee, G Targher, CP Day
Nature reviews Gastroenterology & hepatology 10 (6), 330, 2013
11772013
The natural history of nonalcoholic fatty liver: a follow‐up study
MR Teli, OFW James, AD Burt, MK Bennett, CP Day
Hepatology 22 (6), 1714-1719, 1995
11471995
HLA-B* 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
AK Daly, PT Donaldson, P Bhatnagar, Y Shen, I Pe'er, A Floratos, MJ Daly, ...
Nature genetics 41 (7), 816-819, 2009
9512009
Non-alcoholic fatty liver disease: the mist gradually clears
NMW de Alwis, CP Day
Journal of hepatology 48, S104-S112, 2008
9062008
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
European Association for The Study of The Liver, ...
Obesity facts 9 (2), 65-90, 2016
7912016
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers
IN Guha, J Parkes, P Roderick, D Chattopadhyay, R Cross, S Harris, ...
Hepatology 47 (2), 455-460, 2008
7122008
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management
S McPherson, T Hardy, E Henderson, AD Burt, CP Day, QM Anstee
Journal of hepatology 62 (5), 1148-1155, 2015
6742015
Pathogenesis of steatohepatitis
CP Day
Best practice & research Clinical gastroenterology 16 (5), 663-678, 2002
6312002
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
S McPherson, SF Stewart, E Henderson, AD Burt, CP Day
Gut 59 (9), 1265-1269, 2010
6102010
EASL clinical practical guidelines: management of alcoholic liver disease
European Association For The Study Of The Liver
Journal of hepatology 57 (2), 399-420, 2012
5982012
Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease
A Lonardo, LE Adinolfi, P Loria, N Carulli, G Ruggiero, CP Day
Gastroenterology 126 (2), 586-597, 2004
5442004
Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver
MR Teli, CP Day, OFW James, AD Burt, MK Bennett
The Lancet 346 (8981), 987-990, 1995
5251995
Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease
L Valenti, A Al‐Serri, AK Daly, E Galmozzi, R Rametta, P Dongiovanni, ...
Hepatology 51 (4), 1209-1217, 2010
5232010
From fat to inflammation
CP Day
Gastroenterology 130 (1), 207-210, 2006
4872006
The system can't perform the operation now. Try again later.
Articles 1–20